Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.

Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K.

J Korean Med Sci. 2012 Nov;27(11):1364-70. doi: 10.3346/jkms.2012.27.11.1364. Epub 2012 Oct 30.

2.

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.

Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H.

Circ J. 2013;77(5):1337-44. Epub 2013 Feb 2.

3.

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.

Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H.

Cardiovasc Diabetol. 2014 Jul 30;13:110. doi: 10.1186/s12933-014-0110-2.

4.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
5.

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T.

Transl Res. 2012 Jan;159(1):25-31. doi: 10.1016/j.trsl.2011.09.005. Epub 2011 Oct 17.

PMID:
22153807
6.

Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes.

Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P.

Metabolism. 2014 Sep;63(9):1141-8. doi: 10.1016/j.metabol.2014.06.004. Epub 2014 Jun 14.

PMID:
25034387
7.

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.

J Am Heart Assoc. 2013 Jan 28;2(1):e003277. doi: 10.1161/JAHA.112.003277.

8.

Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.

Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R, Takahashi H.

Cardiovasc Diabetol. 2016 Nov 4;15(1):153.

9.

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.

Martens FM, Visseren FL, de Koning EJ, Rabelink TJ.

J Cardiovasc Pharmacol. 2005 Dec;46(6):773-8.

PMID:
16306801
10.

Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.

Takai S, Sakonjo H, Jin D.

J Pharmacol Sci. 2014;125(4):386-93. Epub 2014 Jul 17.

11.

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.

PMID:
18476982
12.

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H.

J Am Coll Cardiol. 2012 Jan 17;59(3):265-76. doi: 10.1016/j.jacc.2011.07.053.

13.

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006739. doi: 10.1002/14651858.CD006739.pub2. Review.

PMID:
18425967
14.

Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.

Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K; PROLOGUE Study Investigators.

Cardiovasc Diabetol. 2016 Sep 13;15(1):134. doi: 10.1186/s12933-016-0438-x.

15.

Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

Lumb AN, Gallen IW.

Diabet Med. 2009 Feb;26(2):189-90. doi: 10.1111/j.1464-5491.2008.02645.x. No abstract available.

PMID:
19236626
16.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Zerilli T, Pyon EY.

Clin Ther. 2007 Dec;29(12):2614-34. doi: 10.1016/j.clinthera.2007.12.034. Review.

PMID:
18201579
17.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
18.

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

Lage MJ, Fabunmi R, Boye KS, Misurski DA.

Adv Ther. 2009 Feb;26(2):217-29. doi: 10.1007/s12325-009-0002-0. Epub 2009 Feb 14.

PMID:
19219409
19.

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ.

Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514.

PMID:
19691426
20.

Supplemental Content

Support Center